TY - JOUR
T1 - Prolactin concentrations in antipsychotic-naïve patients with schizophrenia and related disorders
T2 - A meta-analysis
AU - González-Blanco, Leticia
AU - Greenhalgh, Anne Marie D.
AU - Garcia-Rizo, Clemente
AU - Fernandez-Egea, Emilio
AU - Miller, Brian J
AU - Kirkpatrick, Brian
N1 - Funding Information:
Dr. González-Blanco was supported by a grant from the Spanish Foundation of Psychiatry and Mental Health. Also, this author has received speaker fees and travel expenses for attending conferences from Janssen, Otsuka, Pfizer and Lundbeck.
Funding Information:
Dr. Miller has nothing to disclose for the work under consideration. In the past 12 months, Dr. Miller reports employment at Georgia Regents University, grant support from the National Institute of Mental Health (K23MH098014), the American Psychiatric Association (Kempf Fund Award) and Georgia Regents University; research support from the National Institutes of Health Clinical Loan Repayment Program; honoraria from psychiatric Times; and speaker fees for lectures from the University of Nevada-Reno.
Funding Information:
Dr. Fernandez-Egea has received unrestricted research funding from Genus Pharmaceuticals, and consultancy fees from Roche/Genentech. He is partially supported by a Young Investigator Award (NARSAD).
Publisher Copyright:
© 2016 Elsevier B.V.
PY - 2016/7/1
Y1 - 2016/7/1
N2 - Objective: The use of dopaminergic antagonist antipsychotics is associated with hyperprolactinemia, but some studies have found increased prolactin concentrations in antipsychotic-naive patients with schizophrenia and related disorders. We conducted a systematic review and meta-analysis of studies of prolactin in antipsychotic-naïve patient with these disorders (PRISMA No. CRD42015016337). Data sources: PubMed (Medline), PsycInfo, and Web of Science were searched for articles from 1950 to the present in English. Study selection: Seven studies of males (N = 141 for patients, N = 191 for control subjects) and five studies of females (N = 67 and N = 116) met criteria for inclusion: data on blood prolactin concentrations for both control subjects and antipsychotic-naive patients with schizophrenia or a related disorder, with data available separately for males and females. Data extraction: Data was extracted from the papers by one author and independently verified by a second. Results: The mean effect size for males was 1.02 (95% CI, 0.77, 1.26; p < 0.001) and 0.43 for females (95% CI 0.11, 0.76; p < 0.01). Meta-regression analyses for age, smoking, body mass index (BMI), year of publication, and cortisol were not significant. Funnel plots did not suggest the presence of a publication bias. Conclusions: Our meta-analyses found significantly increased prolactin levels in both male and female antipsychotic-naïve patients with schizophrenia and related disorders. The small number of studies and limited matching for potentially confounding variables in some of the studies were limitations of this analysis. Prolonged hyperprolactinemia may lead to sexual dysfunction and osteoporosis, and some antipsychotics cause additional elevation of prolactin concentrations.
AB - Objective: The use of dopaminergic antagonist antipsychotics is associated with hyperprolactinemia, but some studies have found increased prolactin concentrations in antipsychotic-naive patients with schizophrenia and related disorders. We conducted a systematic review and meta-analysis of studies of prolactin in antipsychotic-naïve patient with these disorders (PRISMA No. CRD42015016337). Data sources: PubMed (Medline), PsycInfo, and Web of Science were searched for articles from 1950 to the present in English. Study selection: Seven studies of males (N = 141 for patients, N = 191 for control subjects) and five studies of females (N = 67 and N = 116) met criteria for inclusion: data on blood prolactin concentrations for both control subjects and antipsychotic-naive patients with schizophrenia or a related disorder, with data available separately for males and females. Data extraction: Data was extracted from the papers by one author and independently verified by a second. Results: The mean effect size for males was 1.02 (95% CI, 0.77, 1.26; p < 0.001) and 0.43 for females (95% CI 0.11, 0.76; p < 0.01). Meta-regression analyses for age, smoking, body mass index (BMI), year of publication, and cortisol were not significant. Funnel plots did not suggest the presence of a publication bias. Conclusions: Our meta-analyses found significantly increased prolactin levels in both male and female antipsychotic-naïve patients with schizophrenia and related disorders. The small number of studies and limited matching for potentially confounding variables in some of the studies were limitations of this analysis. Prolonged hyperprolactinemia may lead to sexual dysfunction and osteoporosis, and some antipsychotics cause additional elevation of prolactin concentrations.
KW - Meta-analysis
KW - Prolactin
KW - Psychosis
KW - Schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=84962383366&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84962383366&partnerID=8YFLogxK
U2 - 10.1016/j.schres.2016.03.018
DO - 10.1016/j.schres.2016.03.018
M3 - Review article
C2 - 27068570
AN - SCOPUS:84962383366
SN - 0920-9964
VL - 174
SP - 156
EP - 160
JO - Schizophrenia Research
JF - Schizophrenia Research
IS - 1-3
ER -